30.07
0.21 (0.70%)
| Previous Close | 29.86 |
| Open | 29.75 |
| Volume | 434,330 |
| Avg. Volume (3M) | 296,325 |
| Market Cap | 966,515,968 |
| Price / Earnings (TTM) | 24.65 |
| Price / Earnings (Forward) | 5.51 |
| Price / Sales | 2.18 |
| Price / Book | 5.26 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | 6.61% |
| Operating Margin (TTM) | 13.71% |
| Diluted EPS (TTM) | 1.22 |
| Quarterly Revenue Growth (YOY) | 22.70% |
| Quarterly Earnings Growth (YOY) | -91.30% |
| Total Debt/Equity (MRQ) | 411.94% |
| Current Ratio (MRQ) | 1.08 |
| Operating Cash Flow (TTM) | 198.44 M |
| Levered Free Cash Flow (TTM) | 341.32 M |
| Return on Assets (TTM) | 7.95% |
| Return on Equity (TTM) | 19.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 3.00 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 117.12% |
| 52 Weeks Range | ||
| Median | 44.00 (46.33%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Aug 2025 | 44.00 (46.33%) | Buy | 36.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Collegium to Participate in Upcoming Investor Conferences |
| 25 Aug 2025 | Announcement | Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting |
| 07 Aug 2025 | Announcement | Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook |
| 24 Jul 2025 | Announcement | Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 |
| 07 Jul 2025 | Announcement | Collegium Announces $150 Million Share Repurchase Program |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |